9.38
-0.18(-1.88%)
Currency In USD
| Previous Close | 9.56 |
| Open | 9.5 |
| Day High | 9.68 |
| Day Low | 9.34 |
| 52-Week High | 28.18 |
| 52-Week Low | 5.9 |
| Volume | 2.7M |
| Average Volume | 4.44M |
| Market Cap | 971.61M |
| PE | -1.79 |
| EPS | -5.23 |
| Moving Average 50 Days | 8.52 |
| Moving Average 200 Days | 12.07 |
| Change | -0.18 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $424.43 as of July 01, 2025 at a share price of $9.38. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $426.36 as of July 01, 2025 at a share price of $9.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewswire Inc.
Jun 15, 2025 2:45 PM GMT
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demons
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
GlobeNewswire Inc.
May 18, 2025 11:25 AM GMT
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were p
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financi